Background
Intrahepatic cholangiocarcinoma (ICC) is a devastating malignancy that arises from the epithelial lining of the intrahepatic bile ducts; recent data have demonstrated an increase in the incidence and mortality of ICC worldwide [
1]. Due to the difficulty in detecting ICC at the early stage and the disappointing chemotherapy strategies offered currently, the prognoses of patients with advanced cholangiocarcinoma are very poor [
2,
3]. Therefore, new insights into cancer cell-specific biological pathways are urgently needed to promote development of rationally targeted and more effective therapeutics.
Even under aerobic conditions, cancer cells preferentially undergo glycolysis followed by fermentation; this phenomenon is known as aerobic glycolysis (or the Warburg effect) [
4]. Lactic dehydrogenase A, LDH-5 (LDH-A), the NADH-dependent enzyme that catalyzes the conversion of pyruvate to lactate, is a key glycolytic enzyme for aerobic glycolysis. Inhibition of LDH-A has been shown to cause a blockade of aerobic glycolysis of tumor cells [
5] and to severely diminish the tumorigenicity of neu-initiated mammary tumor cells [
6,
7]. Previous studies have shown that LDH-A is strongly expressed in gastric, pulmonary, gynecologic, and breast malignancies associated with poor prognoses [
8‐
10]. However, the expression of LDH-A in clinical tissue samples of ICC has not been previously described, and the effects of LDH-A in ICC have been unclear.
In metazoan cells, reactive oxygen species (ROS) are generated by mitochondria during oxidative phosphorylation (OXPHOS) [
11]. Under normal conditions, ROS appear to promote cell growth. In contrast, they activate and modulate apoptosis when cells are under stress [
12]. As a key effector of cell death, ROS inflict oxidative damage on cellular proteins, lipids, and nucleic acids. In advanced tumors, however, these agents are downregulated, and consequent cell-death signaling is suppressed [
13]. Considering that aerobic glycolysis diminishes cellular ROS in yeast [
14], we hypothesized that silencing LDH-A by blocking aerobic glycolysis might upregulate ROS levels and induce apoptosis of ICC.
In the ICC tissues examined in the present study, LDH-A was overexpressed and the expression of LDH-A was associated with tumor differentiation. Reduction of LDH-A by RNA interference (RNAi) inhibited cell growth in liquid culture and induced cell apoptosis. Furthermore, the inhibition of LDH-A elevated cytoplasmic ROS levels. In other words, overexpression of LDH-A in cholangiocarcinoma might be associated with ROS downregulation. Taken together, these results suggest that LDH-A is a potential therapeutic target for ICC treatments.
Methods
Reagents and cell lines
Cholangiocarcinoma cell lines (HuCCT-1 cells) were purchased from the Chinese Academy of Sciences. Dulbecco’s modified Eagle’s medium (DMEM), phosphate-buffered saline (PBS), fetal bovine serum (FBS), non-essential amino acid solution (NEAA 10 mM, 100×), penicillin-streptomycin solution (10,000 units/ml penicillin and 10,000 μg/ml of streptomycin) and trypsin-ethylenediaminetetraacetic acid (EDTA) solution (0.05% trypsin, 0.53 mM EDTA) were obtained from Invitrogen-Life Technologies (Carlsbad, CA, USA).
ICC tissue samples
Paraffin-embedded samples of ICC were obtained from 42 patients who underwent surgical excision without any prior therapy between 2010 and 2011 at The First Affiliated Hospital of Nanjing Medical University. The para-carcinoma tissue we choose were 1 cm or more away from the cancerous tissue. Histological diagnoses and grading were performed on hematoxylin-eosin-stained tissue sections. All patients had given informed consent. The study was approved by the Institutional Review Board of The First Affiliated Hospital of Nanjing Medical University. The patients’ clinical data are listed in Table
1. A total of 32/42 patients were mass-forming, 8/42 were periductal-infiltrating, and 2/42 were intraductal-growing cholangiocarcinomas. Histologically, all patients enrolled had tubular adenocarcinomas.
Table 1
Correlation between LDH-A expression level and clinicopathologic characteristics in ICC patients
Sex | Male | 10 | 10 | 0.554 |
| Female | 13 | 9 | |
Age, years | >55 | 9 | 13 | 0.058 |
| ≤55 | 14 | 6 | |
Tumor size, cm | >6 | 9 | 9 | 0.591 |
| ≤6 | 14 | 10 | |
Grade | 1 | 6 | 11 | 0.037 |
| 2/3 | 17 | 8 | |
Lymph node | Yes | 9 | 4 | 0.207 |
metastasis | No | 14 | 15 | |
Immunohistochemistry
First, the 4-μm tissue sections were deparaffinized with xylene and rehydrated. Antigen retrieval was performed by autoclaving for 10 minutes. Endogenous peroxidase activity was quenched with methanol and hydrogen peroxide (2.5% to 3.5%) for five to eight minutes, then the sections were washed for three minutes in PBS three times. The primary antibody against LDH-A (dilution 1:100; ab9002, Abcam, Cambridge, UK) was applied at room temperature and the sections placed in the refrigerator at 4°C overnight.
Following washing with PBS (three times for three minutes), tissue sections were incubated with a rabbit anti-sheep IgG (Bioworld Products, Visalia, CA, USA) at 37°C for 30 minutes. Then the sections were washed in PBS. Streptavidin peroxidase reagent was applied for 10 minutes. The color was developed via a three- to five-minute incubation with 3,3′-diaminobenzidine (DAB) solution. Finally, the sections were counterstained with hematoxylin for five to eight minutes and mounted on glass specimen plates.
Treated tissue sections were observed under an optical field with 200× magnification. According to the percentage of positive cells in the cytoplasm and the nuclear expression, which was assessed in a grading system [
15], two LDH-A expression levels were established: strong cytoplasmic expression in >50% of cancer cells or nuclear expression in >10% of cancer cells was defined as high expression; otherwise, nuclear expression was considered low.
Silencing LDH-A with RNA interference
The target sequence for LDH-A small interfering RNA was 5′-GGAGAAAGCCGUCUUAAUU-3′. The control nucleotide sequence of small interfering RNA was 5′-GTTCTCCGAACGTGTCACGT-3′. This random sequence is not related to LDH-A mRNA. The pGPU6/Neo eukaryotic expression vector with LDH-A siRNA (shRNA) or LDH-A siRNA con (NC) was transiently transfected into the HuCCT-1 cell line using Lipofectamine2000 reagent according to the manufacturer’s protocol (Invitrogen). The interference effect was verified by RT-PCR and western blot assay at 48 and 72 hours post-transfection.
Real-time PCR
The mRNA levels of LDH-A and β-actin were analyzed using real-time PCR. Briefly, 2 μg of high-quality RNA was processed directly to cDNA in a total volume of 25 μl using a reverse transcription kit (Takara, Dalian, China) according to the manufacturer’s instructions. Amplification reactions were performed in a 50-μl volume of SYBR Premix Ex Taq (Takara, DRR041A). The PCR reaction included the following components: 10 pmol of primer, 2 mM MgCl2, 200 μM dNTP mixture, 0.5 U of Taq DNA polymerase and universal buffer. The thermal cycling conditions were as follows: 95°C for 30 seconds; 40 cycles at 95°C for 5 seconds, 60°C for 31 seconds; and a final dissociation stage. The specificity of amplification was examined by melting curve analysis and by electrophoresis in 2% agarose gel. All of the reactions were performed in triplicate in an ABI PRISM 7300 real-time PCR system. The primer sequences for the human LDH-A gene were as follows: forward primer, 5′-AGCCCGATTCCGTTACCT-3′ and reverse primer: 5′-CACCAGCAACATTCATTCCA-3′. As an internal standard, a fragment of human β-actin was amplified by PCR using the following primers: forward primer, 5′-CCAAAGCAACCGTGAGGA-3′ and reverse primer, 5′-CCAGAGGCGTACAGGACA-3′. Data are presented as the fold change of LDH-A expression in each tumor tissue relative to its paired control group tissue after normalization with β-actin.
Western blot analysis
Cells were harvested and lysed in a buffer containing 50 mM Tris–HCl pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% Triton and 1 mM PMSF for 20 minutes on ice. Lysates were cleared by centrifugation at 17,970 × g, 4°C for 10 minutes. Supernatants were collected, and protein concentrations were determined using a Bradford assay (Beyotime, Wuhan, China). The proteins were then separated with an SDS/polyacrylamide gel and transferred to a polyvinylidene fluoride (PVDF) membrane (Bio-Rad, Berkeley, CA, USA). After blocking in PBS with 5% non-fat dry milk for 1 hour, the membranes were incubated overnight at 4°C with the primary antibodies in PBS with 5% non-fat dry milk. Anti-LDH-A rabbit antibody (1:1000, Cell Signaling Technology, Danvers, MA, USA) and anti-β-actin polyclonal antibody (1:2000, Bioss International, Shanghai, China) were used. Membranes were extensively washed with PBST and incubated with horseradish peroxidase-conjugated secondary anti-mouse antibody or anti-rabbit antibody (1:2,000, Bio-Rad). After additional washes with PBST, antigen-antibody complexes were visualized with a chemiluminescence kit (Pierce, Thermo-Fisher Scientific, Waltham, MA, USA).
Cell viability assay
To analyze the effect of LDH-A on the viability of HuCCT-1, a total of 3 to 5 × 103 cells per well were seeded in 96-well plates. After 12 hours, the cells were transfected with shRNA or NC plasmids and incubated for 96 hours. Cell viability was determined using a Cell Counting Kit-8 assay according to the manufacturer’s protocol (Dojindo Laboratories, Kumamoto, Japan) at 24, 48, 72, and 96 hours after transfection.
Cell apoptosis assay
To analyze apoptosis, cells with or without treatment were stained with annexin-V–fluorescein isothiocyanate (FITC) and 7-aminoactinomycin D (7-AAD), according to the manufacturer’s instructions (Becton Dickinson Biosciences, San Jose, CA, USA). Data acquisition and analyses were performed using a FACScan flow cytometer with Cell-Quest software (BD Biosciences). Cells that were positively stained by annexin-V-FITC only (early apoptosis) and were positive for both annexin-V–FITC and 7-AAD (late apoptosis) were quantitated, and both subpopulations were considered as dead cells.
Measurement of levels of intracellular ROS
Intracellular ROS production was measured by staining cells with carboxy-H2 dichlorofluorescin diacetate (DCFDA; molecular probes) according to the manufacturer’s instructions (Beyotime, Wuhan. China). Briefly, treated HuCCT-1 cells were cultured in the presence of 20 μM carboxy-H2DCFDA for 30 minutes. After removing the culture medium, cells were washed twice with PBS, resuspended in growth medium and measured by flow cytometry.
Statistics
Results are expressed as mean ± standard deviation (SD). The χ2 test was used to test relationships between categorical variables including age, gender, tumor size, grade, lymph node metastasis and the expression of LDH-A. Independent-sample t-tests were used to compare LDH-A mRNA, the proliferation, apoptosis, and ROS levels between the RNAi and the negative control (NC) groups. Statistical significance was considered P <0.05.
Discussion and conclusions
The principal result of our experiments was the finding that the expression of LDH-A was higher in ICC. This result agrees with the observation of Wang
et al. that the LDH-A gene is up-regulated in ICC cells compared to normal liver tissues [
17]. An increase of LDH-A in tumor cells is linked with an aggressive phenotype in colorectal adenocarcinomas. In other studies of gastric carcinoma, the overexpression of LDH-5 was more prevalent in advanced tumors having positive vessel invasion, and patients with overexpression of LDH-5 showed far lower disease-free and overall survival rates compared with patients with low LDH-5 expression; therefore, LDH-A expression may be a useful prognostic factor for patients with gastric carcinoma [
10,
15]. Our study revealed a significant correlation between LDH-A and clinicopathologic characteristics (Table
1); poorly differentiated ICC cells tended to have higher expression of LDH-A. In conclusion, LDH-A is overexpressed in ICC and could, therefore, serve as an additional marker for malignancy.
Earlier studies have shown that attenuation of LDH-A expression causes impairment of tumor maintenance and leads to a reduction in tumor growth in xenograft models of renal cancer [
6,
18]. Here, we observed that knockdown of LDH-A in the ICC cell line HuCCT-1 is associated with the reduction of the proliferation rate and an increase in the apoptosis rate. Our research supports the hypothesis that the upregulation of LDH-A creates an adaptive advantage by which cancer cells evade apoptosis. The high expression of LDH-A in cancer cells causes cancer cells to use aerobic glycolysis rather than OXPHOS as their main means of glucose metabolism. This allows these cells to sustain higher proliferative rates and to resist some cell death signals, particularly those mediated by increased oxidative damage [
14,
19]. Therefore, cancer-specific isoforms of enzymes involved in the Warburg effect (such as LDH-A) may represent new drug targets for ICC treatment [
20,
21]. Individuals with a hereditary LDH-A deficiency show myoglobinuria only after intense anaerobic exercise (exertional myoglobinuria), and they do not show any symptoms under ordinary circumstances. So LDH-A may be, in principle, a specific, tolerated, and effective antitumor target for ICC.
These pro-apoptosis effects of the down-regulation of LDH-A in ICC could be attributed to a decrease in ROS. Reduction of LDH-A has been reported to promote oxidative phosphorylation [
6], with the result of inducing apoptosis through the mitochondrial pathway [
22]. Our finding that ROS levels increased remarkably in the RNAi group agreed with these reports. We infer that an increased sensitivity to oxidative stress may be a major mechanism for the pro-apoptotic effect of reduced LDH-A expression.
In general, the results of our experiments indicate that LDH-A is highly expressed in ICC and that inhibition of LDH-A causes remarkable apoptosis of the HuCCT-1 cell line. Therefore, LDH-A might be a specific therapeutic target for ICC. Furthermore, our results indicate that ROS levels are linked with the expression of LDH-A and may be the cause of the pro-apoptotic effect induced by the reduction of LDH-A expression in ICC.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YY and ML carried out the molecular genetic studies, participated in the clinical studies and drafted the manuscript. ZF participated in the design of the study and performed the manuscript review. RL carried out the literature research and data acquisition. JC participated in the data analysis and statistical analysis. HF carried out the manuscript editing. All authors read and approved the final manuscript.